Philip Morris International: ZYNsn't It?

“Given our strong year-to-date and expected full-year performance, we are well on track to exceed our 2024-2026 CAGR targets, which already represent a best-in-class growth profile within consumer packaged goods. With such strong progress already delivered and an exciting growth outlook over the coming years, we look forward with confidence to 2026 and beyond.” - Emmanuel Babeau, PMI CFO, Q3 2025 Remarks

Isn’t it peculiar that US ZYN garnered the majority of investors’ focus in Q3 and took the lion’s share of questions during the PMI Q&A? Mixed signals were presented: growth still under that of the category, albeit a reacceleration of off-take, offset by a weaker margin due to heightened promotion. Rather than being a surprise, the related results merely represented a natural evolution of the factors documented in Under Pressure, Per-Pouch Price Premium, Defiance, and company-specific notes throughout the year.

PMI’s management stated that the degree of promotion witnessed in Q3’25 was temporary, and that the company wanted to make a ‘blast’ due to ZYN supply fully normalizing. However, it appears that the blast rendered shrapnel, some of which has landed firmly in PMI’s knee. PMI states its goal is to grow the nicotine pouch category in the US significantly. As far as that effort goes, they are succeeding. Higher awareness and lower prices will do that. The company also cites capturing incremental volume and value share. But will that capture level be sustained, and will the elevated promotion not be quite as fleeting as they say?